An interventional study of Stereotactic body radiation therapy (SBRT) in Ventricular Tachycardia, sponsored by Cancer Research Antwerp. Recruiting at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Cancer Research Antwerp · Not applicable, Interventional, and Treatment
Among 21 studies in Tachycardia, Ventricular with a site in Belgium — 4 open to participants now, 4 under way, none of them phase 3. Tachycardia, Ventricular · Belgium.
Among the 21 studies in Tachycardia, Ventricular with a site in Belgium, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, and was the 21st registered.
452 studies on the registry are indexed under Tachycardia, Ventricular; 121 are open to participants now.
Browse Tachycardia, Ventricular studies →4 of the 21 studies in Tachycardia, Ventricular with a site in Belgium are open now. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in Belgium, France, Lithuania
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 86 Tachycardia, Ventricular studies recruiting now, 67 (78%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 70 across 281 interventional studies indexed under Tachycardia, Ventricular.
Median enrollment 153 across the 15 interventional studies, 1,018 across the 6 observational. Of the 16 that completed or were terminated, 8 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 21 have an industry lead sponsor. The 10 most frequent:
Cancer Research Antwerp is the lead sponsor of 12 studies on the registry; 8 are open to participants now.
Cancer Research Antwerp has 1 study filed under Tachycardia, Ventricular — fewer than ten, so there is no comparison to draw.
1 of the studies in Tachycardia, Ventricular with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07116525Biosense Webster, Inc.A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter | 2027-02-07 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Tachycardia, Ventricular with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigator-initiated, CArdiac Stereotactic radiation Treatment for Ablation of ventRicular tachycardia (CASTAR) study will be conducted in patients with ventricular tachycardia (VT) which is either refractory to antiarrhythmic medication therapy in maximal dose or to catheter ablation or with contraindications to antiarrhythmic medication or catheter ablation.
The study is a non-randomized, multicenter, interventional study of cardiac SBRT, for which a total dose of 25 Gy will be delivered in a single fraction using volumetric modulated arc therapy (VMAT). The aim of the CASTAR study is to assess the feasibility and the safety of cardiac SBRT for the treatment of VT. Secondary objectives are efficacy, toxicity and QoL of cardiac SBRT for Ventricular tachycardia .
The study will be conducted at multiple centers across Belgium. Twenty patients will be enrolled to the study. Interim analyses are planned to be performed when the first five or ten subjects have been treated. Participation in the study will comprise a screening period, where screening assessments must be completed before starting treatment. Eligible, consenting patients will then undergo SBRT, which is limited to a single dose delivery on one day. During SBRT, patients are closely monitored in accordance with the DEGRO guidelines for radiotherapy in patients with ICDs (Gauter-Fleckenstein 2015). After SBRT, patients will be closely monitored during a 3-5 days hospitalization. The post-treatment phase will start after patients are discharged from the hospital. Patients will be followed on regular basis to assess safety and efficacy of SBRT treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single radiation dose of 25 Gy is delivered to the VT target.
Radiation: Stereotactic body radiation therapy (SBRT)
Stereotactic body radiation therapy (SBRT): a single radiation dose of 25 Gy is delivered to the VT target.
Feasibility of SBRT for the treatment of ventricular tachycardia
Feasibility will be assessed as the successful implementation and completion of cardiac SBRT without interruption of treatment. SBRT consists of a single fraction of 25 Gy delivered to the ventricular tachycardia target.
Time frame: Day of SBRT treatment (Day 1)
Safety of SBRT for the treatment of ventricular tachycardia.
Safety will be assessed by the incidence and severity of adverse events related to radiotherapy following cardiac SBRT. Adverse events will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0.
Time frame: From SBRT treatment through 31 days after SBRT
Change in ventricular tachycardia burden following SBRT
The ventricular tachycardia (VT) burden will be assessed by the number of VT episodes recorded by ECG and implantable cardioverter-defibrillator (ICD) readouts. The number of VT episodes during the 6 months following SBRT will be compared with the number during the 6 months preceding SBRT. A 6-week blanking period immediately following SBRT will be taken into account in the analysis of VT recurrences.
Time frame: 6 months before SBRT through 6 months after SBRT
Time from SBRT to first VT recurrence
Time from SBRT treatment to the first documented recurrence of ventricular tachycardia, as determined from ICD readouts. A 6-week blanking period following SBRT will be considered in the analysis of VT recurrence.
Time frame: From SBRT through 36 months after treatment
Time from SBRT to first sustained ventricular tachycardia or ICD shock
Time from SBRT treatment to the first occurrence of sustained ventricular tachycardia or the first appropriate ICD shock during follow-up.
Time frame: From SBRT through 36 months after treatment
Time from SBRT to first ventricular tachycardia storm
Time from SBRT treatment to the first occurrence of a ventricular tachycardia storm during follow-up.
Time frame: From SBRT through 36 months after treatment
Change in the number of electrical storms following SBRT
The number of electrical storms occurring following SBRT will be compared with the number occurring before SBRT treatment.
Time frame: 6 months before SBRT through 6 months after SBRT
Change in anti-tachycardia pacing and ICD shocks following SBRT
The number of anti-tachycardia pacing (ATP) interventions and ICD shocks following SBRT will be compared with the number occurring before SBRT treatment.
Time frame: 6 months before SBRT through 6 months after SBRT
Change in anti-arrhythmic medication use following SBRT
Anti-arrhythmic medication use will be assessed during follow-up. The type and dosage of anti-arrhythmic drugs will be collected to evaluate changes in the need for anti-arrhythmic treatment following SBRT.
Time frame: From baseline through 36 months after SBRT
Overall survival following SBRT
Overall survival will be assessed from the date of SBRT treatment until death from any cause.
Time frame: From SBRT through 36 months after treatment
Incidence of heart transplantation following SBRT
The number and proportion of participants requiring heart transplantation during follow-up will be assessed.
Time frame: From SBRT through 36 months after treatment
Incidence of cardiac arrhythmic mortality following SBRT
The number and proportion of participants who die from a cardiac arrhythmic cause during follow-up will be assessed.
Time frame: From SBRT through 36 months after treatment
Incidence of cardiac non-arrhythmic mortality following SBRT
The number and proportion of participants who die from a cardiac non-arrhythmic cause during follow-up will be assessed.
Time frame: From SBRT through 36 months after treatment
Incidence and severity of acute radiation-related adverse events
The incidence and severity of adverse events related to radiotherapy will be assessed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0. Acute adverse events are defined according to the time period specified in the protocol.
Time frame: Through 90 days after SBRT
Incidence and severity of late radiation-related adverse events
The incidence and severity of late adverse events related to radiotherapy will be assessed and graded according to NCI CTCAE version 5.0.
Time frame: The protocol defines late adverse events as those occurring more than 90 days after starting radiotherapy.
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Feb 2032, 72 months after the start.
Of 86 non-industry interventional studies with no phase under Tachycardia, Ventricular, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 70. This study's planned 72 months is above that.
Counting every sponsor, half of 126 studies reached it within 36 months; a quarter within 20 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cancer Research Antwerp